Zai adds second bispecific to pipeline via Regeneron deal

In Zai’s latest deal giving it local rights to a therapeutic developed in the West, the Shanghai-based biotech has partnered with Regeneron for REGN1979, a bispecific antibody that is in Phase II testing to treat B cell non-Hodgkin

Read the full 386 word article

How to gain access

Continue reading with a
two-week free trial.